FREE ACCESS TO THE LATEST RESEARCH
Welcome to the European Journal of Cancer’s Advances in Melanoma Resource Centre.
The Resource Centre, edited by Prof. Reinhard Dummer, Dr. Paolo Ascierto and Dr. James Larkin, will provide you with the latest research on melanoma, including a selection of original research and review articles from some of the world’s leading journals, case studies, and other educational material.
New articles will be added to the Resource Centre regularly and are openly available to our readers.
Paper of the month – November 2014
Editorial comment by Prof. R. Dummer:
This month we have decided to present two papers. Both papers were published in the New England Journal of Medicine and report on two prospective randomized trials investigating the clinical outcome of a monotherapy with a BRAF inhibitor versus a combination therapy using a BRAF inhibitor and a MEK inhibitor in patients with BRAF mutated advanced melanoma. In both studies there is a clear advantage for the combination therapy with an increase in progression free survival resulting in an improvement of approximately 40% with an improved response rate. The phase III clinical trial presented by Long reached its primary endpoint progression free survival and the secondary endpoint overall survival. Taking together these studies clearly support combination therapy with a BRAF and MEK inhibitor as the standard of care for BRAF mutated melanoma.
Georgina V. Long, M.D., Ph.D., Daniil Stroyakovskiy, M.D., Helen Gogas, M.D., Evgeny Levchenko, M.D., Filippo de Braud, M.D., James Larkin, M.D., Claus Garbe, M.D., Ph.D., Thomas Jouary, M.D., Axel Hauschild, M.D., Ph.D., Jean Jacques Grob, M.D., Ph.D., VN Engl J Med 2014; 371:1877-1888November 13, 2014DOI: 10.1056/NEJMoa1406037
James Larkin, M.D., Ph.D., Paolo A. Ascierto, M.D., Brigitte Dréno, M.D., Ph.D., Victoria Atkinson, M.D., Gabriella Liszkay, M.D., Michele Maio, M.D., Mario Mandalà, M.D., Lev Demidov, M.D., Daniil Stroyakovskiy, M.D., Luc Thomas, M.D., Ph.D., Luis de laN Engl J Med 2014; 371:1867-1876November 13, 2014DOI: 10.1056/NEJMoa1408868
NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Helen Tucker, Nwamaka Umeweni, Janet Robertson, Jane AdamThe Lancet Oncology, Early Online Publication, 22 October 2014
Guoli Chen MD, PhD, Jonathan Dudley MD, Li-Hui Tseng MD, PhD, Kirstin Smith BS, Grzegorz T. Gurda MD, PhD, Christopher D. Gocke MD, James R. Eshleman MD, PhD, Ming-Tseh Lin MD, PhD
Alba Diaz, MD , Joan Anton Puig-Butillé, PhD , Concha Muñoz , Dolors Costa, PhD , Anna Díez, MSc , Adriana Garcia-Herrera, MD, PhD , Cristina Carrera, MD, PhD , Celia Badenas, PhD , Francesc Solé, PhD , Josep Malvehy, MD, PhD , Susana Puig, MD,PhD, et.al.Journal of the American Academy of Dermatology Volume 71, Issue 4, Pages 839–841, October 2014
About the editors
- Professor Dummer is Vice-Chairman of the Department of Dermatology and Head of the Skin Cancer Unit at the University Hospital...
- Dr James Larkin, FRCP PhD is a Medical Oncologist specialising in the treatment of patients with cancer of the kidney...
- Dr. Paolo A. Ascierto is Director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute ‘Fondazione...